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Deficiency of t h e enzyme d i h y d r o p t e r i d i n e r e d u c t a s e (DHPR) causes a syndrome of hyperphenylalaninemia and mental r e t a r da t i o n b u t i s r e f a c t o r y t o conventional d i e t a r y therapy. An antibody a g a i n s t sheep DHPR was used t o i d e n t i f y c l o n e s f o r human DHPR from a human l i v e r cDNA e x p r e s s i o n l i b r a r y . The f u l l l e n g t h cDNA c l o n e comprises 1560 b a s e s , codes f o r a p r o t e i n of 244 amino a c i d s and 25,774 d a l t o n s , and t h e p r e d i c t e d amino a c i d sequence matches an incomplete amino a c i d sequence of sheep DHPR. The cDNA was recombined i n an e u k a r y o t i c e x p r e s s i o n v e c t o r and introduced i n t o c u l t u r e d c e l l s by DNA mediated gene t r a n s f e r .
C e l l s transformed w i t h t h e recombinant gene expressed DHPR p r o t e i n and enzymatic a c t i v i t y a t l e v e l s 50% of human l i v e r . Analysis of f i b r o b l a s t s from f i v e u n r e l a t e d i n d i v i d u a l s g e n e t i c a l l y d e f i c i e n t i n DHPR by southern and n o r t h e r n b l o t t i n g i n d i c a t e s t h a t t h e DHPR gene is g r o s s l y i n t a c t and t h a t DHPR mRNA is t r a n s c r i b e d .
These r e s u l t s i n d i c a t e d t h a t t h e mutat i o n s causing DHPR d e f i c i e n c y a r e n o t l a r g e d e l e t i o n s of t h e DHPR l o c u s . These experiments a l s o demonstrate t h e f e a s i b i l i t y of r e c o n s t i t u t i n g DHPR a c t i v i t y by gene t r a n s f e r of t h e recomb i n a n t c l o n e and i n t r o d u c e s t h e p o s s i b i l i t y of e x p l o r i n g somatic gene replacement therapy of DHPR d e f i c i e n c y .
FOLATE DEFICIENCY INDUCED HOMOCYSTEINEMIA. J.Y. LIN, S.S. Kang, J . Zhou and P.W.K Wong. Rush Medical College, P r e s b y t e r i a n -S t . Luke's Medical Center.
Department of P e d i a t r i c s , S e c t i o n of Genetics, c h i c a g o , I l l i n o i s .

In humans on a normal d i e t , about 50% of homocysteine i s remethylated t o methionine with m e t h y l t e t r a h y d r o f o l a t e a s t h e methyl donor. Hence, f o l a t e d e f i c i e n c y may r e s u l t i n inadequate s y n t h e s i s o f t h e methyl donor, l e a d i n g t o homocysteine accumulat i o n . Moderate homocysteinemia has been a s s o c i a t e d with a t h e r os c l e r o t i c v a s c u l a r d i s o r d e r s i n humans but o t h e r c o n t r i b u t o r y f a c t o r s have not been excluded.
To s t u d y the e f f e c t of i s o l a t e d f o l a t e d e f i c i e n c y , 2 groups of 45 r a t s were given ( 1 ) adequate f o l a t e o r ( 2 ) f o l a t e d e f i c i e n t chemically defined d i e t s . Five r a t s i n each group were k i l l e d bi weekly f o r serum chemical a n a l y s i s . 812 and pyridoxine remained f f e r e n c e s i n f o l a t e and t o t a l homocvsteine between the 2 groups were s t a t i s t i c a l l y s i g n i f i c a n t (~< 0 . 0 0 1 ) . Serum f o l a t e i n r a t s from 4-10 weeks and from 12-20 weeks was s i m i l a r respect i v e l y t o low normal and subnormal l e v e l i n humans observed t o have moderate homocysteinemia. This r a i s e s q u e s t i o n s regarding normal serum f o l a t e v a l u e s and f o l a t e requirement i n humans. 1023 Euglycemia in insulin df ndent diabetes mellitus (IDDM) is possible with intensive insulin treatment. Though control may be improved, t h e risks of hypoglycemia are increased We have encountered a patient with IDDM who attempted intensive insulin treatment only t o experience debilitating migraine attacks in association with insulin induced hypoglycemia Seven year-old boy developed IDDM and managed by conventional insulin therapy (2 injections mixed insulin/day, uriae glucose monitoring) for two years. On occasion he experienced early AM headaches with vomiting in association with hypoglycemia. Neurologic evaluations indicated that he was experiencing migraine attacks. At the same time he was enrolled in an adult diabetic clinic which had the goal of maintaining his blood glucose between 100-160 mg/dl. Frequent severe usually early AM headaches with prolonged vomiting triggered by hypoglycemia led t o metabolic derangement and many hospitalizations over t h e next 18 months Maintenance propranolol started for migraine prevention; intensity and frequency of hypoglycemia and migraine attacks increased Conventional diabetic management resumed with lessening of frequency and severity of hypoglycemia and migraine episodes Then propranolol discontinued, and no symptomatic hypoglycemia, migraine or hospitalization for past year. Counter regulatory mechanisms t o prevent insulin induced hypoglycemia are usually intact in t h e young diabetic, and migraine is an unexpected complication of hypoglycemia, particularly in a child This boy showed symptoms of hypoglycemia. that had a unique and repetitive expression tie also showed that children may not tolerate an adult oriented intensive insulin management p l a n Disappearance of serum ICA following d i a g n o s i s of d i a b e t e s i s w e l l documented and may be r e l a t e d t o a d e c l i n e i n a v a i l a b l e a n t igen. Reversion of ICA p o s i t i v e t o n e g a t i v e i s otherwise r a r e . We r e p o r t two e x c e p t i o n a l c a s e s : Case 1 whose r e v e r s i o n from ICA p o s i t i v e t o n e g a t i v e was followed i n 29 months by type 1 d i a b e t e s and Case 2 who presented w i t h i n s u l i n o p e n i c ICA p o s i t i v e d i a b e t e s m e l l i t u s w i t h p r o g r e s s i v e d e c l i n e i n i n s u l i n requirements, l o s s of ICA and r e t u r n t o normal glucose t o l e r a n c e over 33 months. Case 1 s u g g e s t s t h a t ICA may be a t r a n s i e n t marker of a p e r s i s t i n g underlying immune p r o c e s s leading t o complete i s l e t d e s t r u c t i o n . 
,El
HYPERINSULINEXIA I N TRANSGENIC MICE CARRYING MULTIPLE COPIES OF THE HUMAN INSULIN GENE: EVIDENCE FOR A GENE
